(NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced today a research collaboration and global license agreement to develop a preclinical bispecific molecule with
The research collaboration will incorporate
Janssen Biotech, Inc.
proprietary DART® platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology.
“We are excited to collaborate with Janssen, which we believe is a leader in the field of next generation antibody-based therapeutics, by bringing together our two companies’ respective scientific talent and experience to leverage our DART platform to generate a compelling product candidate that addresses unmet patient needs,” said
Scott Koenig, M.D., Ph.D., President and Chief Executive Officer of
Under the terms of the agreement, Janssen will pay
an upfront payment of
and will be responsible for funding all expenses.
will also be eligible to receive up to
in potential milestone payments and tiered royalties on worldwide product sales. Further details about the transaction are not disclosed.
Read the full article at: ir.macrogenics.com
- About the Author
- Latest Posts
Over the past 11 years, Chris has grown BioBuzz into a respected brand that is recognized for its community building, networking events and news stories about the local biotech industry. In addition, he runs a Recruiting and Marketing Agency that helps companies attract top talent through a blended model that combines employer branding and marketing services together with a high powered recruiting solution.